South Korea-based startup Astrogen and Paris-based firm Iktos have announced a research collaboration to use Artificial Intelligence (AI) platform for drug design against a novel Parkinson’s Disease target.

Under the terms of the agreement, Iktos will apply its proprietary active learning based deep docking and de novo structure-based generative modelling technologies to design and optimize novel compounds and expedite the identification of pre-clinical drug candidates targeting an undisclosed target for the treatment of Parkinson’s disease.

Astrogen will contribute to in-vitro/in-vivo efficacy screening of lead compounds/pre-clinical drug candidates and will lead the entire development process from pre-clinical stage.

The companies will share responsibility for generating lead compounds and pursuing the optimal development path for selecting pre-clinical drug candidates.